214759-22-5

Basic information

• Product Name: (5-CHLOROTHIEN-2-YL)METHYLAMINE
• Synonyms: (5-CHLOROTHIOPHEN-2-YL)METHANAMINE;2-Thiophenemethanamine,5-chloro-(9CI);2-(Aminomethyl)-5-chlorothiophene;5-Chloro-2-thiophenemethanamine;(5-CHLOROTHIEN-2-YL)METHYLAMINE
• CAS NO: 214759-22-5
• Molecular Formula: C₅H₆ClNS
• Molecular Weight: 147.63
• Product Categories: HALIDE
• Mol File: 214759-22-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 76-79℃ (3 Torr)
• Flash Point: 81.144 °C
• Appearance: /
• Density: 1.332g/cm³
• Vapor Pressure: 0.191mmHg at 25°C
• Refractive Index: 1.5630 (589.3 nm 20℃)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.39±0.29(Predicted)
• CAS DataBase Reference: (5-CHLOROTHIEN-2-YL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (5-CHLOROTHIEN-2-YL)METHYLAMINE(214759-22-5)
• EPA Substance Registry System: (5-CHLOROTHIEN-2-YL)METHYLAMINE(214759-22-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 214759-22-5(Hazardous Substances Data)

Usage

General Description

(5-Chlorothien-2-yl)methylamine is a chemical compound often used in the field of pharmaceutical chemistry for the synthesis of various pharmaceutical drugs. (5-CHLOROTHIEN-2-YL)METHYLAMINE is part of the thiophene family (sulfur heterocycles), characterized by its five-membered ring structure of four carbon atoms and one sulfur atom. Its structure also includes a chlorine atom at the 5th position and a methylamine functional group. As an intermediate in the production of different therapeutic drugs, this compound exhibits its importance in scientific research and development. The exact properties like toxicity or potential hazards of this specific compound are not widely documented, implying a necessity for careful handling and usage following strict safety measures.

InChI:InChI=1/C5H6ClNS/c6-5-2-1-4(3-7)8-5/h1-2H,3,7H2

Upstream product

• 1015434-04-4 C₅H₄N₃SCl 
• 24065-33-6 5-Chlorothiophene-2-carboxylic acid 
• 42518-98-9 5-chlorothiophene-2-carbonyl chloride 
• 22353-82-8 5-chlorothiophene-2-carboxamide 
• 1003-31-2 thiophene-2-carbonitrile 
• 401485-19-6 tert-butyl N-(thiophen-2-ylmethyl)carbamate 
• 27757-85-3 2-Aminomethylthiophene 
• 23784-96-5 2-Chloro-5-(chloromethyl)thiophene 
• 96-43-5 2-thienyl chloride 

Downstream Products

• 214755-31-4 N-(5-Chloro-thiophen-2-ylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide 
• 1018480-83-5 C₁₇H₁₃ClF₃N₃O₂S₂ 
• 1123818-87-0 C₂₅H₁₈ClN₃O₂S 
• 1123819-09-9 C₂₅H₁₇Cl₂N₃O₂S 
• 1123819-16-8 C₂₆H₁₇ClF₃N₃O₂S 
• 1123819-36-2 C₂₇H₁₇ClF₃N₃O₂S 
• 438208-71-0 {[(5-chloro(2-thienyl))methyl]amino}-N-[4-(5-chloro-1,3-dioxobenzo[c]azolidin-2-yl)-3-methylphenyl]carboxamide 

Relevant articles and documents

Design and synthesis of heteroaromatic-based benzenesulfonamide derivatives as potent inhibitors of H5N1 influenza A virus

Influenza A virus is an enveloped negative single-stranded RNA virus that causes febrile respiratory infection and represents a clinically challenging threat to human health and even lives worldwide. Even more alarming is the emergence of highly pathogenic avian influenza (HPAI) strains such as H5N1, which possess much higher mortality rate (60%) than seasonal influenza strains in human infection. In this study, a novel series of heteroaromatic-based benzenesulfonamide derivatives were identified as M2 proton channel inhibitors. A systematic investigation of the structure-activity relationships and a molecular docking study demonstrated that the sulfonamide moiety and 2,5-dimethyl-substituted thiophene as the core structure played significant roles in the anti-influenza activity. Among the derivatives, compound 11k exhibited excellent antiviral activity against H5N1 virus with an EC50 value of 0.47 μM and selectivity index of 119.9, which are comparable to those of the reference drug amantadine.

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N6-[(3-halothien-2-yl)methyl]adenosine, N6-[(4-halothien-2-yl)methyl]adenosine, and N6-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N6-[(2-bromothien-3-yl)methyl]adenosine, N6-[(4-bromothien-3-yl)methyl]adenosine, N6-[(5-bromothien-3-yl)methyl]adenosine N6-[(2-chlorothien-3-yl)methyl]adenosine, N6-[(4-chlorothien-3-yl)methyl]adenosine, and N6-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

Systematic structure-activity relationship (SAR) exploration of diarylmethane backbone and discovery of a highly potent novel uric acid transporter 1 (URAT1) inhibitor

In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a-1x and 1ha-1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200-and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.